The government has shelved plans to launch an implementation study of AstraZeneca’s Covid-19 vaccine, which could potentially have answered key questions about whether it protects people from severe disease caused by the new variant dominating transmission in SA.
The health department originally planned to launch SA’s coronavirus vaccine rollout with AstraZeneca’s shot but changed its plans at the 11th hour after evidence emerged that the jab offered minimal protection against mild to moderate disease caused by the 501Y.V2 variant...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.